Introduction and Objective: GLP-1 RAs and SGLT-2i have transformed T2DM management by improving glycemic control, promoting weight loss, and reducing the risk of cardiometabolic-renal disease. This study’s aim was to assess real world prescribing patterns of GLP-1 RAs and SGLT-2i within a large health care system and assess variations across sociodemographic groups.Methods: A retrospective analysis […]
Read MoreMonth: June 2026
2351-P: Assessment of Phenotypic Clustering of Incident and Prevalent Type 2 Diabetes: A MESA Pilot Study in the Definition, Etiology, Function: Integration to Enhance Type 2 Diabetes Treatment (DEFINE-Type 2 Diabetes) Consortium
Introduction and Objective: Phenotypic clustering of T2D into aging-related (MARD), obesity-related (MOD), insulin-deficient (SIDD), and insulin-resistant (SIRD) subgroups may capture heterogeneity, but performance and stability in diverse populations are uncertain.Methods: We performed established k-means clustering models in 871 prevalent and 462 incident T2D cases with data for age at onset, BMI, HbA1c, HOMA2-IR, and HOMA2-β […]
Read More2110-P: Risk Factors for Elevated Blood Pressure in Children with Type 1 Diabetes: Evidence from a Population-Based EHR Cohort and a Pediatric Biobank
Introduction and Objective: Elevated blood pressure (BP) is a common but underrecognized contributor to vascular complications in children with type 1 diabetes (T1D). We aimed to characterize BP patterns and kidney function trajectories in pediatric T1D and to identify clinical, immune, and genetic predictors of elevated BP.Methods: We examined longitudinal patterns of BP and eGFR […]
Read More2614-P: Understanding the Lived Experiences of Dosing Practices among People Living with Obesity (PwO) Using Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RAs) for Weight Loss (WL): A U.S. Qualitative Study
Introduction and Objective: GLP-1 RAs are increasingly used for WL, yet little is known about how PwO experience and personalize treatment in everyday life. This mixed-method study aimed to elucidate the dynamics shaping treatment experiences and dosing practices of PwO using GLP-1 RA in the US.Methods: Public user-generated content from Reddit (N>250,000 posts) and YouTube […]
Read More2609-P: Efficacy and Safety of a Novel Oral Small Molecule GLP-1 Receptor Agonist HDM1002 in Chinese Overweight and Obese Adults: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
Introduction and Objective: HDM1002, a novel, orally bioavailable non-peptide full agonist of GLP-1RA, demonstrated promising weight loss in phase 1 trial. This phase 2 study evaluated the efficacy and safety of HDM1002 in Chinese overweight and obese adults without diabetes mellitus.Methods: In this randomized, double-blind, placebo-controlled, multicenter study (NCT06500299), 185 participants (pts) (BMI 28-40 kg/m²) […]
Read More49-PUB: Targeting Hepatic Oxidative Stress in Diabetes: Antioxidant and Cytoprotective Effects of Hypericum perforatum L. Aerial and Hairy Root Methanolic Extracts
Introduction and Objective: Diabetes mellitus is associated with pronounced hepatic oxidative stress caused by excessive reactive oxygen species production, impaired antioxidant defenses, and activation of stress-responsive signaling pathways. Building on evidence of the antidiabetic potential of Hypericum perforatum L. aerial parts (Hyperici herba, HH) and H. perforatum hairy root (HR) extracts, this study aimed to […]
Read More2636-P: Efsubaglutide Alfa in Overweight or Obesity: Phase 2b ENLIGHT Study
Introduction and Objective: Efsubaglutide alfa (Suba) is a novel GLP-1RA. ENLIGHT is a seamless Phase 2b/3 program; the Phase 2b stage evaluated Suba regimens to inform dose selection for the subsequent Phase 3 study.Methods: This double-blind, placebo (PBO)-controlled trial (NCT06921486) randomized participants to Suba 5, 10, or 20 mg once weekly (QW), 20 mg once […]
Read More
Why Are Ultra-Processed Foods So Bad for You? Study Offers Insight
Share on PinterestThe manufacturing processes used to produce ultra-processed foods are linked to negative impacts on human health. Image Credit: Andy Sacks/Getty Images A recent study has found that it may not just be what’s in ultra-processed foods that makes them unhealthy, but how they’re made. The study noted that factors such as changes in […]
Read More2674-P: Adaptations of Juvenile Offspring Islets to Maternal Overnutrition and Metformin in a Nonhuman Primate Model
Introduction and Objective: Use of the oral glycemic agent metformin (Met) in pregnancy has expanded beyond treatment of maternal diabetes, but effects on offspring metabolic health are understudied. Met is not metabolized by the maternal liver and is transported across the placenta, and in humans is associated with small for gestational age, increased postnatal catch-up […]
Read More1992-P: Impact of Primary Care Availability on Adverse Effects of Social Vulnerability on Diabetes Outcomes
Introduction and Objective: Access to primary care and social determinants of health (SDOH) both impact diabetes care. We aimed to determine whether primary care (assessed as primary care physician [PCP] supply) modifies the association between SDOH and measures of diabetes care among Medicare beneficiaries.Methods: We used 2022 county data on PCP supply from the Area […]
Read More